Statistics from Altmetric.com
Tumour necrosis factor blocking agents such as infliximab have proved to be effective in patients with ankylosing spondylitis as up to 60–70% of the patients meet the 20% response criteria of assessment in ankylosing spondylitis (ASAS).1,2 However, it cannot be explained why 30% of patients fail to respond and develop adverse reactions.
In rheumatoid arthritis, inefficacy to infliximab was associated with low serum trough infliximab levels and the presence of antibodies to infliximab (ATI).3
This study was designed to identify whether infliximab levels and ATI predict clinical inefficacy and adverse events in ankylosing spondylitis.
Eight patients with active ankylosing spondylitis (fulfilling the 1984 modified New York Criteria …